Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants
- 27 February 2026
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , 3269-3276
Abstract
Purpose: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, HapB3) are well-established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP toxicity. Experimental Design: Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any cancer with available DPYD genetic data were included. The primary endpoint was a composite of CTCAE grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results: Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of uncommon deleterious variants (1.1% of patients) had significantly higher toxicity risk than non-carriers (67% vs. 24%; adjusted OR 7.36; 95% CI 1.75–38.20; p = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants vs. testing only the validated variants (positive predictive value: 44.1% vs. 40.0%). Conclusions: Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences (UM1TR004404)
This publication has 42 references indexed in Scilit:
- Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesBritish Journal of Clinical Pharmacology, 2025
- Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosingInternational Journal of Cancer, 2025
- A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeClinical Pharmacology & Therapeutics, 2025
- Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal CancerJAMA Network Open, 2024
- Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity riskBiomedicine & Pharmacotherapy, 2022
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon CancerJAMA, 2021
- A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex‐Biased PhenotypesClinical Pharmacology & Therapeutics, 2019
- Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysisInternational Journal of Cancer, 2018
- Gene‐Specific Variant Classifier (DPYD‐Varifier) to Identify Deleterious Alleles of Dihydropyrimidine DehydrogenaseClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017